Whole Exome Sequencing Identified Two Single Nucleotide Polymorphisms of Human Leukocyte Antigen-DRB5 in Familial Sarcoidosis in China.

IF 3.8 4区 医学 Q2 GENETICS & HEREDITY
Qian Zhang, Zuojun Xu, Hui Huang, Meijun Zhang
{"title":"Whole Exome Sequencing Identified Two Single Nucleotide Polymorphisms of Human Leukocyte Antigen-DRB5 in Familial Sarcoidosis in China.","authors":"Qian Zhang,&nbsp;Zuojun Xu,&nbsp;Hui Huang,&nbsp;Meijun Zhang","doi":"10.2174/1566523223666230119143501","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Sarcoidosis is a multisystem granulomatous disorder whose etiology is related to genetic and immunological factors. Familial aggregation and ethnic prevalence suggest a genetic predisposition and inherited susceptibility to sarcoidosis.</p><p><strong>Objective: </strong>This study aimed to identify suspected risk loci for familial sarcoidosis patients.</p><p><strong>Methods: </strong>We conducted whole exome sequencing on two sarcoidosis patients and five healthy family members in a Chinese family for a case-control study. The two sarcoidosis patients were siblings who showed chronic disease.</p><p><strong>Results: </strong>The Gene Ontology results showed single nucleotide polymorphisms in three genes, including human leukocyte antigen (<i>HLA)-DRB1, HLA-DRB5, and KIR2DL4</i>, associated with both 'antigen processing and presentation' and 'regulation of immune response.' Sanger sequencing verified two nonsynonymous mutations in <i>HLA-DRB5</i> (rs696318 and rs115817940) located on 6p21.3 in the major histocompatibility complex (MHC) class II beta 1 region. The structural model simulated on Prot- Param protein analysis by the Expert Protein Analysis System predicted that the hydropathy index changed at two mutation sites (rs696318: p.F96L, -1.844 to -1.656 and rs115817940: p.T106N, -0.322 to -0.633), which indicated the probability of changes in peptide-binding selectivity.</p><p><strong>Conclusion: </strong>Our results indicated that two nonsynonymous mutations of <i> HLA-DRB5</i> have been identified in two sarcoidosis siblings, while their healthy family members do not have the mutations. The two <i>HLA-DRB5</i> alleles may influence genetic susceptibility and chronic disease progression through peptide mutations on the MHC class II molecule among the two affected family members.</p>","PeriodicalId":10798,"journal":{"name":"Current gene therapy","volume":"23 3","pages":"215-227"},"PeriodicalIF":3.8000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current gene therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2174/1566523223666230119143501","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"GENETICS & HEREDITY","Score":null,"Total":0}
引用次数: 1

Abstract

Background: Sarcoidosis is a multisystem granulomatous disorder whose etiology is related to genetic and immunological factors. Familial aggregation and ethnic prevalence suggest a genetic predisposition and inherited susceptibility to sarcoidosis.

Objective: This study aimed to identify suspected risk loci for familial sarcoidosis patients.

Methods: We conducted whole exome sequencing on two sarcoidosis patients and five healthy family members in a Chinese family for a case-control study. The two sarcoidosis patients were siblings who showed chronic disease.

Results: The Gene Ontology results showed single nucleotide polymorphisms in three genes, including human leukocyte antigen (HLA)-DRB1, HLA-DRB5, and KIR2DL4, associated with both 'antigen processing and presentation' and 'regulation of immune response.' Sanger sequencing verified two nonsynonymous mutations in HLA-DRB5 (rs696318 and rs115817940) located on 6p21.3 in the major histocompatibility complex (MHC) class II beta 1 region. The structural model simulated on Prot- Param protein analysis by the Expert Protein Analysis System predicted that the hydropathy index changed at two mutation sites (rs696318: p.F96L, -1.844 to -1.656 and rs115817940: p.T106N, -0.322 to -0.633), which indicated the probability of changes in peptide-binding selectivity.

Conclusion: Our results indicated that two nonsynonymous mutations of HLA-DRB5 have been identified in two sarcoidosis siblings, while their healthy family members do not have the mutations. The two HLA-DRB5 alleles may influence genetic susceptibility and chronic disease progression through peptide mutations on the MHC class II molecule among the two affected family members.

全外显子组测序发现中国家族性结节病人白细胞抗原drb5的两个单核苷酸多态性。
背景:结节病是一种多系统肉芽肿性疾病,其病因与遗传和免疫因素有关。家族聚集性和种族患病率提示结节病的遗传易感性和遗传易感性。目的:本研究旨在确定家族性结节病患者的可疑危险位点。方法:对一个中国家庭的2例结节病患者和5名健康家庭成员进行全外显子组测序,进行病例对照研究。2例结节病患者为兄弟姐妹,均表现为慢性疾病。结果:基因本体结果显示三个基因的单核苷酸多态性,包括人类白细胞抗原(HLA)-DRB1, HLA- drb5和KIR2DL4,与“抗原加工和呈递”和“免疫反应调节”相关。Sanger测序证实了HLA-DRB5的两个非同义突变(rs696318和rs115817940)位于主要组织相容性复合体(MHC) II类β 1区6p21.3上。通过Expert protein analysis System对Prot- Param蛋白分析模拟的结构模型预测,两个突变位点(rs696318: p.F96L, -1.844 ~ -1.656, rs115817940: p.T106N, -0.322 ~ -0.633)亲水指数发生了变化,这表明多肽结合选择性发生变化的可能性。结论:我们的研究结果表明,在两个结节病兄弟姐妹中发现了两个HLA-DRB5非同义突变,而他们的健康家庭成员没有突变。这两个HLA-DRB5等位基因可能通过MHC II类分子的肽突变影响遗传易感性和慢性疾病的进展。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Current gene therapy
Current gene therapy 医学-遗传学
CiteScore
6.70
自引率
2.80%
发文量
46
期刊介绍: Current Gene Therapy is a bi-monthly peer-reviewed journal aimed at academic and industrial scientists with an interest in major topics concerning basic research and clinical applications of gene and cell therapy of diseases. Cell therapy manuscripts can also include application in diseases when cells have been genetically modified. Current Gene Therapy publishes full-length/mini reviews and original research on the latest developments in gene transfer and gene expression analysis, vector development, cellular genetic engineering, animal models and human clinical applications of gene and cell therapy for the treatment of diseases. Current Gene Therapy publishes reviews and original research containing experimental data on gene and cell therapy. The journal also includes manuscripts on technological advances, ethical and regulatory considerations of gene and cell therapy. Reviews should provide the reader with a comprehensive assessment of any area of experimental biology applied to molecular medicine that is not only of significance within a particular field of gene therapy and cell therapy but also of interest to investigators in other fields. Authors are encouraged to provide their own assessment and vision for future advances. Reviews are also welcome on late breaking discoveries on which substantial literature has not yet been amassed. Such reviews provide a forum for sharply focused topics of recent experimental investigations in gene therapy primarily to make these results accessible to both clinical and basic researchers. Manuscripts containing experimental data should be original data, not previously published.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信